Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4165 - Treatment paradigm shift in NSCLC: patient data analysis from 2005 to 2016

Date

09 Sep 2017

Session

Poster display session

Presenters

Laura Mitrofan

Citation

Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380

Authors

L. Mitrofan1, M. Sahni2, D. Dhingra2, H. Mistry3, C. Anger3

Author affiliations

  • 1 Global Oncology, Rwi, QuintilesIMS, 92088 - Paris/FR
  • 2 Global Delivery Center, QuintilesIMS, 122022 - Gurgaon/IN
  • 3 Global Oncoloy, Rwi, QuintilesIMS, N1 9JY - London/GB
More

Resources

Abstract 4165

Background

In the last decade, chemotherapies were the SoC in advanced NSCLC treatment with limited benefit to long-term survival. Discovery of EGFR/ALK and PD1/PDL1 followed by of approval targeted therapies (TTs) and immunotherapies (IOs), respectively, marked two major treatments shifts. In addition, science advancement on drug resistance issued from TTs and new drug gable mutations continue to transform the treatment landscape and options for patients with advanced NSCLC.

Methods

This study used IMS Oncology Analyzer™ a syndicated, retrospective, longitudinal cancer treatment database collecting anonymized patient-level oncology data in EU5, projected to national level. Data collected between 2005 and 2016 was used to identify changes in the treatment paradigm in advanced NSCLC. Three time period groups have been compared: period 1: from 2005 to 2008; period 2: from 2009 to 2014 and period 3: 2015 and 2016.

Results

Of the currently 1,602,026 (projected number) treated populations, there is an increase in protein kinase Inhibitors (TKIs) usage, mainly represented by anti EGFR and anti ALK, from 8% to 23% to 30% in period 1, 2 and period 3 respectively. Monoclonal antibodies (MAb) follows a similar trend increasing from 1% to 15% in the last years, respectively, while the platinum agents slightly decreases. IOs captures 52% in the last couple of years from the overall MAb group. Till recently, bevacizumab (BEVA) was leading this therapeutic class. Increased granularity in patient stratification, will allow identification of more spectacular treatment changes or identification of those who would have passed unnoticed. In 1L, mutant segment, paradigm switch occurred end 2008 when TKIs reached directly 84%. In 2L, IOs jump is much less noticeable, entering directly in the last analyzed period with 25% from MAb group. In WT segment, we can notice 2 switches: one in 1L, end 2014 when BEVA reached directly 13% and a second one in 2L, end 2016, when MAbs captured 28%, with IOs representing 90% from this therapeutic group.

Conclusions

Currently, the advent of IOs has completely overshadowed existing TTs. Emerging genetic markers (ROS-1, KRAS, RET), specific EGFR/ALK mutations due to resistance along with combinations of IOs and TTs will continue to add new treatment options.

Clinical trial identification

NONE

Legal entity responsible for the study

QuintilesIMS

Funding

QuintilesIMS

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.